Neuroprotective effect of cajaninstilbene acid against cerebral ischemia and reperfusion damages by activating AMPK/Nrf2 pathway

Hui Xu a,b, Jiangang Shen c, Jianbo Xiao d, Feng Chen a, Mingfu Wang a,b,*

a Institute for Advanced Study, Shenzhen University, Shenzhen 518060, China
b School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong, China
c School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Sassoon Road, Hong Kong, China
d International Research Center for Food Nutrition and Safety, Jiangsu University, Zhenjiang 212013, China

ARTICLE INFO

Article history:
Received 6 June 2020
Revised 18 July 2020
Accepted 20 July 2020
Available online 23 July 2020

Keywords:
Neuroprotection
Cajaninstilbene acid
Nrf2
AMP-activated protein kinase
Ischemic stroke

ABSTRACT

Introduction: Ischemic stroke is one of the leading causes of death worldwide. Recently, neuroprotection is regarded as an important preventative and therapeutic strategy for ischemic stroke. Cajaninstilbene acid (CSA), a unique stilbenoid with a styryl group, is a potential neuroprotective agent.

Objectives: Hence, this study aimed to evaluate the neuroprotective effect and molecular mechanism of CSA against cerebral ischemia/reperfusion (I/R) damages.

Methods: Cerebral ischemia was modeled by oxygen and glucose deprivation (OGD) in SH-SY5Y cells or transient intraluminal suture middle cerebral artery occlusion (MCAO) in rats, and tert-butyl hydroperoxide (t-BHP) was used to induce oxidative stress in SH-SY5Y cells. CSA (2.5, 5 mg/kg) was intraperitoneally given upon reperfusion after 2 h of MCAO. The signaling pathways were analyzed by Western blotting and inhibitor blocking.

Results: CSA possessed significant neuroprotective activity, as evidenced by the reduced cell death in OGD/R or t-BHP injured SH-SY5Y cells, and decreased infarct volume and neurological deficits in...
Introduction

Neuroprotection is the approach to protect neurons from different pathological factors under several abnormal cerebral conditions, such as Parkinson’s diseases, ischemic stroke and traumatic brain injury. Neuroprotective agents can be administrated before the onset of these neurological diseases to reduce the related risk factors or after the onset of diseases to prevent the spreading of injuries from neurons to neighboring ones [1]. Notably, the development of neuroprotective agents for ischemic stroke has drawn much attention in recent years. Ischemic stroke is caused by the occlusion of cerebral arteries, leading to the deprivation of glucose and oxygen to the blocked brain tissue, which then causes a series of damaging events to neurons including energy depletion, intracellular Ca\(^2+\) accumulation, excitotoxicity, free radical release and inflammation [2]. To tangle with this ischemic condition is to achieve reperfusion via thrombolytic therapy, mainly intravenous injection of recombination tissue plasminogen activator (r-tPA), as soon as possible. However, reperfusion would further promote free radical release and inflammation, causing secondary injuries to neurons [3]. Hence, neuroprotection is necessary for ischemic stroke patients, and many events or molecular targets can be modulated to produce potential protective effects within the cascade of cerebral ischemia and reperfusion (I/R).

Oxidative stress is one of the most important neuroprotective targets. The free radicals generated during cerebral I/R can directly attack brain tissues, triggering mitochondrial dysfunction, inflammation and apoptosis of neurons. Furthermore, free radicals can enhance the permeability of blood–brain barrier via promoting the activation of matrix metalloproteases (MMPs), increasing the risks of cerebral hemorrhage and brain edema [4]. Many studies have focused on evaluating the neuroprotective potential of antioxidants, and one of the most famous agents is edaravone, which is found to reduce cerebral I/R induced brain damages in different ischemic stroke models due to its free radical scavenging activity [5]. Notably, edaravone has been officially approved for the treatment of ischemic stroke in 2001 and amyotrophic lateral sclerosis (ALS) in 2017 [6].

Nuclear factor erythroid 2 related factor 2 (Nrf2) is an important transcriptional factor to regulate the gene expression of diverse cytoprotective proteins, particularly in the antioxidant systems. Once activated, Nrf2 translocates to the nucleus and activates the expression of various antioxidant enzymes, including NAD(P)H quinone oxidoreductase 1 (NQO1) and heme oxygenase-1 (HO-1) [7]. Since Nrf2 is fundamental to the cellular redox homeostasis, some natural Nrf2 activators including sulforaphane and butylhydroquinone have shown remarkable efficacy in different animal models of ischemic stroke [8]. Nrf2 activation is regulated by multiple kinases, such as the mitogen-activated protein kinases (MAPKs), phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) and AMP-activated protein kinase (AMPK). These kinases are reported to promote the Nrf2 translocation to nucleus via regulation of Keap1 or directly phosphorylation on Nrf2 [9,10].

Recently, AMPK mediated Nrf2 activation has been regarded as a critical neuroprotective target. As an example, Wu et al. reported that neferine, a natural alkaloid, could promote Nrf2 activation to protect cerebral I/R injured mitochondria in neurons [11]. Another study suggested that HP-1c, a novel derivative of dl-3-n-butyphthalide, activated the AMPK/Nrf2 pathway to suppress the oxidative stress and inflammation in a transient focal cerebral ischemia model [12].

Pigeon pea (Cajanus cajan (L.)) is traditionally considered to have medical potential, and has been applied to the treatment of various diseases, such as diabetes, osteoporosis and necrosis of femoral head [13]. One of the bioactive components in its leaves is cajaninstilbene acid (3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid, CSA), a stilbenoid composed of a styryl group and the scaffold of aspirin. CSA has recently drawn much attention due to its broad range of bioactivities, including anti-viral, anti-inflammatory, anti-oxidative, anti-bacterial, and cytoprotective effects, as well as treatment of osteonecrosis of femoral head and postmenopausal osteoporosis [14,15]. Recently, we were focusing on screening neuroprotective agents for ischemic stroke from natural stilbenoids and flavonoids, and have found that some natural products that possessed a styryl group exerted stronger activities. Besides, some preliminary data showed that CSA prevented corticosterone-induced mitochondrial apoptosis in PC12 cells [16]. Furthermore, CSA was found to activate the Nrf2/ARE pathway in HepG2 cells at very low concentration [17]. Based on those facts, it is reasonable to hypothesize that CSA might possess the neuroprotective activity against cerebral I/R injuries. Hence, the aim of this study is to investigate the neuroprotective effect of CSA in cerebral I/R injuries and its underlying protective mechanisms.

Materials and methods

CSA preparation

CSA (purity of 98%) was extracted from the leaves of pigeon pea in our lab. Briefly, the leaves of pigeon pea were smashed and immersed in water. The water extracts were then absorbed with macroporous resins and eluted by distilled water, 10% ethanol and 80% ethanol in turn. The eluant with 80% alcohol was collected in our lab. Briefly, the leaves of pigeon pea were smashed and immersed in water. The water extracts were then absorbed with macroporous resins and eluted by distilled water, 10% ethanol and 80% ethanol in turn. The eluant with 80% alcohol was collected...
and dried by rotary evaporation, after which the residue was dissolved in 95% ethanol, dried again, and re-dissolved in ethyl acetate. CSA was then precipitated from the saturated solution of ethyl acetate. The chemical structure of CSA was identified by chromatographic and spectral analysis and shown in Fig. 1 [18].

Cell line, cell models and drug treatment

SH-SY5Y neuroblastoma cells was obtained from American Type Culture Collection (ATCC, VA, USA). They were cultured at 37 °C with the high glucose DMEM medium (Gibco, Gaithersburg, USA) supplemented with 10% FBS (Gibco, Gaithersburg, USA) and 1% penicillin–streptomycin (Gibco, Gaithersburg, USA) in a humidified atmosphere of 5% CO2. Two cell models were used in this study: oxygen and glucose deprivation/reoxygenation (OGD/R) model and tert-butyl hydroperoxide (t-BHP) induced oxidative stress model. OGD/R model was established according to Feng et al. [19]. Briefly, cells were washed with PBS (Sigma, St. Louis, USA), and then cultured with no glucose DMEM (Gibco, Gaithersburg, USA) in a hypoxia chamber (Billups-Rothenberg, Delmar, USA) perfused with 95% N2 and 5% CO2 for 8 h at 37 °C. After that, cells were cultured at the normal cultural conditions for another 16 h to achieve reoxygenation. t-BHP-induced oxidative stress model was performed by treating cells with 100 μM of t-BHP (Sigma, St. Louis, USA). Cells were pretreated with CSA for 24 h before they were subjected to OGD/R or t-BHP damages. The inhibitors, including SB203580 (p38 MAPK & AKT, 5 μM), SP600125 (JNK, 5 μM), U0126 (Erk1/2, 10 μM) [20], BML-275 (AMPK, 5 μM) [21] and brusatol (Nrf2, 0.5 μM, Sigma, St. Louis, USA) [22], were added along with CSA if needed.

Cell viability and lactate dehydrogenase (LDH) release

Cell viability was measured with the Cell Counting Kit-8 (CCK-8, Dojindo Laboratories, Kumamoto, Japan). Cells were incubated with the CCK-8 solution in DMEM medium (1:10) for 1.5 h, and then absorbance was measured at 450 nm. LDH release was evaluated via detecting the LDH level in the cultural supernatant with a Pierce LDH Cytotoxicity Assay kit (Thermo Fisher Scientific, Waltham, USA).

Mitochondrial membrane potential (ΔΨm)

JC-1 probe was used to detect the ΔΨm of SH-SY5Y cells. Briefly, cells were stained with 10 μg/ml JC-1 (Beyotime Institute of Biochemistry, Shanghai, China) at 37 °C in the dark for 30 min and washed with PBS. Fluorescence was analyzed with the flow cytometer and cells with a higher ratio of green signals to red signals was considered to possess the decreased ΔΨm.

Cytochrome c release

Cytochrome c release was detected with the Cytochrome c Releasing Apoptosis Assay kit (Abcam, Cambridge, UK) by detecting the cytochrome c content in cytoplasm. Briefly, cells were collected and homogenized with a Dounce tissue grinder. The supernatant of the homogenate was collected as the cytosolic fraction. Cytochrome c content was then analyzed by the standard Western blotting procedure with the monoclonal mouse anti-cytochrome c antibody. β-actin was used as the internal control.

Na+-K+ ATPase (NKA) and Ca2+-Mg2+ ATPase (CMA) activity

The ATPase activities were measured with the Minim ATP Enzyme Test kit (Nanjing Jiancheng bioengineering institute, Nanjing, China) via measuring the inorganic phosphorus produced by enzymatic ATP hydrolysis. Briefly, cells were collected, homogenized, and then NKA and CMA activities in the homogenate were measured, respectively. One unit of ATPase was defined as the amount of enzyme that generated 1 μM inorganic phosphate in 1 h at 37 °C. Protein content of the homogenate was measured with bicinchoninic acid (BCA) method to normalize the results.

Intracellular reactive oxygen species (ROS) detection

Intracellular ROS was measured with the DCFH-DA fluorescent probe. Cells were incubated with 10 μM DCFH-DA (Sigma, St. Louis, USA) in the dark for 40 min at 37 °C and washed three times with PBS. Fluorescence was then analyzed by the flow cytometer. The ROS contents were expressed as the mean fluorescence intensity of stimulated samples versus that of control.

Superoxidase dismutase (SOD) activity and malondialdehyde (MDA) content

Intracellular SOD and MDA levels were measured with the SOD and MDA detecting kits (Nanjing Jiancheng bioengineering institute, Nanjing, China), respectively. Briefly, cells were collected, homogenized, and then centrifuged to get the supernatant. SOD was measured with the WST-1 method, and one unit of SOD was defined as the amount of SOD that inhibited 50% of the WST-1 formazan production. MDA was detected with the TBA (thiobarbituric acid) method. Protein content of supernatant was measured using the BCA method to normalize the results.

Animal model and drug treatment

The transient intraluminal suture middle cerebral artery occlusion (MCAO) rat model was used in this research. The use of animals in this study was approved by the Committee on the Use of Live Animals in Teaching and Research, The University of Hong Kong (CULATR 4765-18). Adult male Sprague Dawley rats (250–280 g) were supplied by the Laboratory Animal Unit, The University of Hong Kong. Rats were raised at 22 ± 2 °C with 12 h light and 12 h dark. The MCAO/R model was conducted according to Feng et al. [19]. Briefly, rats were firstly anesthetized with 4% isoflurane (Abbott, USA), and then maintained with 2% isoflurane during the whole operation process. The left common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were exposed, and nerves around the arteries were carefully dissected. After that, a stump was made on ECA to insert a monofilament coated with silicon on the tip (0.36 mm, Jialing Co. Ltd., China). The monofilament was advanced from ECA to ICA and then to the root of the middle cerebral artery (MCA) to achieve cerebral ischemia. After ischemia for 2 h, the monofilament was removed and the blood flow to MCA was restored. The sham control rats underwent the same operation of MCAO rats, but no monofilament was inserted to block the MCA. Rats were randomly divided into 6 groups: sham control, MCAO/R control, 2.5 mg/kg CSA, 5 mg/kg CSA, 2 mg/kg brusatol and 5 mg/kg CSA + 2 mg/kg brusatol groups. CSA was dissolved in the mixture of ethanol (45%), PEG400 (25%), and saline (30%). Drugs were intraperitoneally (i.p.) injected immediately after reperfusion. The sham control and MCAO/R control rats were intraperitoneally injected with the same volume of the mixture solution (45% ethanol, 25% PEG400 and 30% saline).

Neurological scores and infarct volume

Neurological scores were obtained by testing rats with the modified neurological severity score (mNSS) scale at 24 h after reperfusion. The mNSS scale ranges from 1 to 18 points, including motor,
sensory, and reflex tests. A higher score indicates more severe neurological damages [23]. Infarct volume was evaluated with TTC staining. Briefly, after reperfusion for 24 h, rats were sacrificed through cardiac perfusion with PBS. Brain tissues were then collected, sliced into 2 mm coronal section and stained with 2% TTC solution at 37 °C for 20 min. The stained slices were photographed and analyzed with Image J. Infarct volume was calculated as (right hemisphere size – red part size of left hemisphere)/(right hemisphere size × 2) × 100%.

Nuclear Nrf2 translocation

Nuclear Nrf2 translocation was evaluated by measuring Nrf2 content in nucleus. Cytoplasmic and nuclear fraction were separated with the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, Waltham, USA). Nrf2 content in the nuclear extract was further tested by the standard Western blot procedure. Histone H3 (HH3) was used as the internal control. Data were analyzed with the Image J software.

Western blotting

Cells or brain tissues were lysed with RIPA buffer (Thermo Fisher Scientific, Waltham, USA) containing 1 mM PMSF (Sigma, St. Louis, USA) and phosphate inhibitor cocktails (Sigma, St. Louis, USA), and total proteins were collected. SDS-PAGE was used to separate the proteins (10 μg), and separated proteins were then transferred to the polyvinylidene fluoride (PVDF) membrane (Bio-rad, Hercules, USA). The membrane was blocked with 5% nonfat milk or BSA (bovine serum albumin, Sigma, St. Louis, USA) and incubated with the corresponding primary antibodies overnight at 4 °C. After being washed with TBST, the membrane was then incubated with horseradish peroxidase-conjugated anti-mouse (Santa Cruz Biotechnology, Dallas, USA) or anti-rabbit (Abcam, Cambridge, UK, 1:5000) secondary antibodies for 1 h at room temperature. Protein bands were visualized with an enhanced chemiluminescence (ECL) substrate kit (Bio-rad, Hercules, USA) and analyzed with the Image J software. Primary antibodies used in this research were as follows. Antibodies from Abcam (Cambridge, UK): Cytochrome c (ab110325, 1:250), Nrf2 (ab31163, 1:1000) and HO-1 (ab13243, 1:2000); Antibodies from Cell signaling technology (Danvers, USA): NQO1 (62262, 1:1000), Keap1 (8047, 1:1000), p-Erk1/2 (4370, 1:2000), p-Akt (9271, 1:2000), p-p38 MAPK (4511, 1:1000), p-p38 MAPK (8690, 1:1000), p-JNK (9255, 1:1000), JNK (9252, 1:1000), p-AMPK (2535, 1:1000), AMPK (5831, 1:1000), HH3 (4499, 1:2000) and β-actin (3700, 1:5000).

Statistical analysis

All data were presented as mean ± standard deviation (SD) of at least three independent experiments using the SPSS statistics 22 (IBM). Differences between the means of the individual groups were assessed by one-way analysis of variance (ANOVA) followed by the Tukey’s test. Differences were considered significant at P < 0.05.

Results

CSA showed neuroprotection both in vitro and in vivo

OGD/R model was widely used to mimic the cerebral I/R conditions in vitro, so the neuroprotective effect of CSA was firstly evaluated in SH-SY5Y cells with OGD/R model. As shown in Fig. 2A, CSA enhanced the cell viability that was decreased by OGD/R damages, indicating its protective effects against OGD/R-induced injuries. Oxidative stress played critical role in cerebral I/R induced damages. Fig. 2 indicated that CSA reduced cell death induced by t-BHP (a ROS inducer), as evidenced by the increased cell viability (Fig. 2B) and reduced LDH release (Fig. 2C). Hence, the protective effect of CSA might be exerted at least partially through reducing the intracellular oxidative stress and its related injuries. In vivo evaluation was done with the MCAO/R rat model. Intraperitoneal injection of CSA was found to reduce the infarct volume and neurological deficits in MCAO/R rats (Fig. 2D–F). In summary, CSA showed neuroprotection against cerebral I/R and oxidative stress induced injuries.

CSA protected SH-SY5Y cells from OGD/R and t-BHP induced oxidative stress

As mentioned above, CSA might attenuate the oxidative stress induced damages, so the antioxidant ability of CSA was further evaluated. Fig. 3 showed that the DCFH-DA fluorescent intensity was lower in CSA-treated cells than that in t-BHP (0.1–1 μM) or OGD/R (0.1–0.5 μM) injured cells, that is, CSA significantly reduced the intracellular ROS level induced by t-BHP and OGD/R damages. Furthermore, MDA was a biomarker of the oxidative stress by reflecting the degree of membrane lipid peroxidation. It was found that both t-BHP and OGD/R damages increased the MDA level in SH-SY5Y cells. However, SH-SY5Y cells showed decreased MDA content after treated with CSA by 33.30% in t-BHP model and 22.12% in OGD/R model (0.5 μM of CSA, Fig. 3). SOD was the first line to defense against the ROS. It was found that SOD activity was also significantly enhanced by CSA treatment (0.1 or 0.5 μM) when compared to t-BHP or OGD/R groups (Fig. 3). Those data implied that CSA reduced the oxidative stress and enhanced the antioxidant ability of SH-SY5Y cells.

CSA alleviated the mitochondrial dysfunction in SH-SY5Y cells

Mitochondria are the main target of oxidative stress and release more free radicals after damaged. To further evaluate the antioxidant and mitochondrial protective activity of CSA, mitochondria function was detected via measuring ΔΨm, cytochrome c release and ATPase activity. JC-1 fluorescence probes, which emitted red signals at normal ΔΨm and green signals at decreased ΔΨm, were used to detect the mitochondrial membrane potential. As shown in Fig. 4A–C, cells damaged by t-BHP showed high percentage of depolarized cells (cells with decreased ΔΨm) and low ratio of red/green signal, implying that t-BHP decreased the ΔΨm of SH-SY5Y cells. After treated with CSA, cells possessed improved ΔΨm, as evidenced by the decreased percentage of depolarized cells and increased ratio of red/green signal compared to t-BHP treated cells. Mitochondrial dysfunction would lead to the release of many pro-apoptotic factors, such as cytochrome c [24]. Fig. 4D indicated that pretreatment of cells with CSA markedly decreased the cytochrome c release, as the cytosolic cytochrome c level of CSA-treated cells was much lower than that of t-BHP treated cells (decreased by 44.17% at 0.5 μM). NKA (sodium pump) and CMA (calcium pump) could sense the changes of oxygen availability and adjust their activity to the ATP production rates, that is, they could reflect the intracellular ATP level and mitochondrial energy metabolism function [25]. It was found that CSA (0.5 μM) enhanced the NKA and CMA activities that were suppressed by t-BHP (Fig. 4E–F). Further studies with OGD/R model also observed the up-regulated NKA and CMA activities by CSA (0.5 μM) treatment (Fig. 4G–H). It could be concluded from the above data that CSA improved the mitochondrial function of t-BHP or OGD/R injured cells, and this protective effect was
Fig. 2. Neuroprotective effect of CSA against cerebral I/R and t-BHP induced injuries. (A) After 24 h of CSA pretreatment, SH-SY5Y cells showed improved cell viability compared to OGD/R damaged cells. (B–C) CSA increased the cell viability and decreased the LDH level in the cultural supernatant of t-BHP injured SH-SY5Y cells. (D–E) CSA was intraperitoneally injected at the onset of reperfusion after 2 h of MCAO. TTC staining was performed after reperfusion for 24 h. It was found that infarct volume was significantly reduced by CSA compared to MCAO/R group (n = 9). (F) Neurological deficits of MCAO/R rats were scored with the mNSS scale at 24 h after reperfusion. CSA was found to decrease the neurological deficits of MCAO/R rats (n = 9). All results were expressed as means ± SD of at least three independent experiments. *$P < 0.05$; **$P < 0.01$ versus control or sham control group; *$P < 0.05$; **$P < 0.01$ versus OGD/R or MCAO/R control group.

Fig. 3. Antioxidant activity of CSA in SH-SY5Y cells. (A) Intracellular ROS level was measured with DCFH-DA dye after 4 h of t-BHP treatment. CSA pretreatment (0.1–1 μM) significantly reduced the ROS level compared to t-BHP group. (B–C) MDA content and SOD activity were measured with corresponding kits after 12 h of t-BHP treatment. CSA decreased the MDA content and increased the SOD activity of t-BHP injured SH-SY5Y cells. (D) Intracellular ROS level was measured after OGD (8 h)/reoxygenation (2 h). SH-SY5Y cells treated with CSA showed lower ROS level than that of OGD/R cells. (E–F) MDA content and SOD activity were measured after reoxygenation for 16 h. After 24 h of CSA pretreatment, cells exhibited reduced MDA content and enhanced SOD activity compared to OGD/R cells. All results were expressed as means ± SD of at least three independent experiments. *$P < 0.05$; **$P < 0.01$ versus control or sham control group; *$P < 0.05$; **$P < 0.01$ versus OGD/R group.
achieved at least partially through reducing the oxidative stress in CSA treated cells.

**CSA promoted Nrf2 activation in both SH-SY5Y cells and MCAO/R rats**

Nrf2 was vital for the systemic antioxidant defense system. To explore the molecular targets that CSA activated to exert its antioxidant activity, key factors of Nrf2 pathway were detected. Nrf2 was kept in the cytoplasm by binding to the Kelch-like ECH-associated protein 1 (Keap1) at normal condition. Under stimulated condition, it was separated from Keap1 and translocated into the nucleus, binding to the ARE (antioxidant responsive element) promoter regions and activating its target genes, such as HO-1 and NQO1 [26]. As shown in Fig. 5A–F, the protein levels of total-Nrf2, nuclear-Nrf2, HO-1 and NQO1 were up-regulated in SH-SY5Y cells after treated with CSA for 24 h, implying that CSA promoted the activation of Nrf2 pathway. Generally, the effective concentrations of CSA for Nrf2 pathway in SH-SY5Y cells were found to be between 0.01 and 1 μM, with the best activity observed at 0.1 or 0.5 μM. The attenuated activity at 1 to 5 μM might be due to the increased cytotoxicity of CSA in SH-SY5Y cells. Furthermore, CSA also increased the protein levels of total-Nrf2, nuclear-Nrf2, HO-1 and NQO1 in t-BHP injured cells (Fig. 5). The nuclear-Nrf2 content of CSA (0.5 μM) treated cells was 27.87% higher than that of t-BHP injured cells (Fig. 5K). Keap1 was down-regulated in CSA treated cells, which was consistent with the enhanced CSA nuclear translocation of CSA (Fig. 5L). Next, the Nrf2 activation was tested in MCAO/R rats. As shown in Fig. 6, promoted Nrf2 nuclear translocation, up-regulated HO-1 and NQO1 expression, and suppressed Keap1 level were also observed in CSA treated MCAO/R rats. Intraperitoneal injection of CSA (5 mg/kg) increased the nuclear-Nrf2 level by 79.93% compared to MCAO/R control rats. Those data indicated that CSA could activate the Nrf2 pathway in normal or t-BHP injured SH-SY5Y cells and MCAO/R rats, and the activation might relate to the regulation of Keap1.

**Inhibition of Nrf2 pathway weakened the neuroprotective effect of CSA**

To explore whether activation of Nrf2 pathway contributed to the neuroprotection of CSA, Nrf2 pathway was suppressed with brusatol, a Nrf2 inhibitor. Fig. 7A indicated that brusatol inhibited the Nrf2 expression in a dose-dependent manner and the inhibitory rate was about 50% at concentration of 0.5 μM, so this concentration was used in the following experiments. Results showed that brusatol weakened the ability of CSA (0.5 μM) to reduce the intracellular ROS level in t-BHP injured SH-SY5Y cells (Fig. 7B). In vivo studies further indicated that brusatol aggravated the MCAO/R injuries and increased the infarct volume of CSA-treated MCAO/R rats, weakening the neuroprotective activity of CSA (Fig. 7C-D). Those data implied that inhibition of Nrf2 by brusatol attenuated the neuroprotective efficiency of CSA both in vitro and in vivo. Hence, Nrf2 pathway might be critical for the antioxidant activity...
of CSA, being at least one of the primary targets for CSA-mediated neuroprotection.

Inhibition of AMPK suppressed CSA induced Nrf2 activation

Nrf2 activation was regulated by multiple kinases, including MAPKs, PI3K/AKT and AMPK, hence the upstream kinases that CSA might regulate to activate the Nrf2 pathway were further studied. Fig. 8A–F indicated that CSA enhanced the phosphorylation of Erk1/2, p38 MAPK and AMPK in SH-SY5Y cells, while the phosphorylation of JNK and AKT was not affected by CSA. The kinases that related to CSA-mediated Nrf2 activation were further screened via applying a series of kinase inhibitors. Fig. 8N–O showed that all the inhibitors tested, including U0126 (Erk1/2 inhibitor), SB203580
(p38 MAPK & AKT inhibitor), SP600125 (JNK inhibitor) and BML-275 (AMPK inhibitor) inhibited the CSA-induced Nrf2 nuclear translocation. Among them, the inhibitory rate of BML-275 was the highest, implying that AMPK might be the dominant kinase which CSA regulated to activate Nrf2 pathway. Hence, the AMPK activation in t-BHP injured SH-SY5Y cells and MCAO/R rats was further tested. As indicated in Fig. 9A–B, CSA enhanced the phosphorylation of AMPK that was decreased by t-BHP or MCAO/R damages. To further study the role of AMPK in CSA-mediated antioxidation, intracellular ROS level in BML-275 treated SH-SY5Y cells were measured. Results showed that BML-275 enhanced the intracellular ROS level of CSA treated cells (Fig. 9C), that is, BML-275 weakened the antioxidant activity of CSA. Those data implied that AMPK was activated by CSA and AMPK/Nrf2 pathway might play essential role in CSA-mediated neuroprotection.

Discussion

So far only a few neuroprotective agents for ischemic stroke have been used clinically. Hence, it is necessary to develop more effective and novel agents for prevention or treatment of ischemic stroke. This study examined the neuroprotective activity of CSA, a unique stilbenoid with a styryl group and the scaffold of aspirin. Aspirin possessed the free radical scavenging activity and was reported to activate the Nrf2/ARE pathway to protect the primary human melanocytes from H2O2 induced damages [27]. It was also found to display neuroprotective effect in spinal cord injury model via activating the Nrf2/HO-1 signaling pathway [28]. As for the styryl group, it might be an effective antioxidant group according to the studies of Hamdi et al., who reported that the coumarin derivatives possessing a styryl functional group exhibited much stronger antioxidant activity than all the other derivatives [29].

Our preliminary data with a group of simple stilbenoids also showed the importance of styryl group in neuroprotection against cerebral I/R damages. For those reasons, it was rational to suggest that CSA possessed good antioxidant activity and might exhibit neuroprotection in ischemic stroke. In this study, cerebral I/R injuries were established with two common models, that is, OGD/R model in SH-SY5Y neuroblast cells and MCAO/R model in SD rats. Our study showed that CSA possessed significant neuroprotective activity, as evidenced by the reduced cell death and oxidative stress in OGD/R injured SH-SY5Y cells and decreased cerebral infarct volume and neurological deficits in MCAO/R rats. The most effective dose of CSA in MCAO/R rats was 5 mg/kg (i.p.) in this study. According to some previous studies, the frequently administered dose of edaravone, a well-known neuroprotective drug, was 3–10 mg/kg (i.p. or i.v.) in the MCAO/R rat model [30]. Hence, the neuroprotective efficiency of CSA was relatively high, raising hope for its potential pharmacological use in ischemic stroke treatment. Besides, the neuroprotective activity of edaravone was primarily due to its antioxidant activity, which proved the effectiveness of antioxidant strategy for neuroprotection in clinical use [31]. CSA also exhibited antioxidant activity in ischemic stroke models, so we then tried to clarify its neuroprotective mechanism with the antioxidant pathway. As far as we know, this was the first study to comprehensively evaluate the neuroprotective activity of CSA against cerebral I/R injuries. Cerebral I/R injuries enhanced the production of ROS, causing the imbalance between the generation and elimination, which
led to inflammation and cell death via destroying proteins, DNAs and RNAs [4]. As mentioned above, we observed the antioxidant activity of CSA in the OGD/R model. To further explore the role of antioxidation in CSA mediated neuroprotection, SH-SY5Y cells was injured with t-BHP, a membrane permeable and relatively stable oxidant compound. t-BHP was commonly used to induced ROS production in cell-based studies [32]. Our studies found that CSA could decrease ROS accumulation, enhance SOD activity, and lower the intracellular MDA content in t-BHP injured cells, and reduce the cell death, indicating that CSA exhibited neuroprotection via reducing I/R induced oxidative stress. Mitochondria were closely related to the intracellular redox homeostasis, in that, they were the main source of ROS, and meanwhile very susceptible to oxidative stress. Excessive ROS led to mitochondrial dysfunction, which then promoted the production of ROS, forming a vicious cycle [33]. Hence, mitochondrial function was further measured in this study. Destruction of the energy metabolism was the most direct change in I/R damaged mitochondria. Normal mitochondrial membrane potential ($\Delta \Psi_m$) helped to maintain the proton gradient across the inner mitochondrial membrane, which was essential for ATP synthase to generate ATP [34]. Loss of $\Delta \Psi_m$ was observed in t-BHP damaged cells, while CSA partially recovered the $\Delta \Psi_m$, which primarily showed the improvement of mitochondrial energy metabolism function. NKA and CMA translocated sodium and potassium or calcium across the plasma membrane using the energy from ATP hydrolysis to maintain the membrane potential and appropriate intracellular calcium level [35]. NKA and CMA could adjust their activity according to the rate of ATP production, so they could be used to evaluate the energy metabolism status [25]. CSA was found to enhance the NKA and CMA activities at the presence of t-BHP or OGD/R injuries, further indicating that energy metabolism was improved after CSA treatment. Another important change of cerebral I/R damaged mitochondria was the formation of mitochondrial membrane permeability transition pore (mPTP) in the inner mitochondrial membrane. mPTP led to the release of a series of pro-apoptotic factors, with cytochrome c to be the most representative one, to promote apoptosis of neurons [24]. CSA improved the mPTP, as evidenced by the reduced cytochrome c release after CSA treatment in t-BHP damaged SH-SY5Y cells. It could be concluded from these data that CSA lowered cellular oxidative stress and reduced the oxidative stress-induced mitochondrial dysfunction in SH-SY5Y cells.

Next, we investigated the underlying antioxidative mechanism of CSA. Nrf2 transcriptional factor, a primary host defense, was a critical important regulator of the intracellular redox status and functional integrity of mitochondria, especially under oxidative stress conditions [36]. Many reports have shown the important cytoprotective role of Nrf2 in cerebral I/R induced injuries and other neurodegenerative diseases. Some unique natural products have been reported to activate the Nrf2 pathway to decrease intra-
cellular oxidative stress and attenuate mitochondrial dysfunction via inducing the expression of various antioxidant enzymes, such as HO-1 and NQO1 [37]. Among them, sulforaphane and tert-butylhydroquinone exhibited good neuroprotection against cerebral I/R injuries and showed great potential in ischemic stroke treatment [8]. As for CSA, it was reported to activate the Nrf2/ARE pathway in HepG2 cells only [17]. In this study, CSA was found to activate the Nrf2 pathway and induce the expression of HO-1 and NQO1 in normal or t-BHP damaged SH-SY5Y cells (0.1–0.5 μM) as well as MCAO/R rats (2.5–5 mg/kg). Hence, Nrf2 path-

Fig. 8. Screening of the upstream kinases that CSA regulated to activate Nrf2. (A–F) SH-SY5Y cells were pretreated with CSA for 24 h and protein levels of the kinases were detected with Western blotting. CSA was found to enhance the phosphorylation of Erk, p38 MAPK and AMPK. (G–M) SH-SY5Y cells were treated with different kinase inhibitors for 24 h and protein levels of the corresponding kinases were detected with Western blotting. (N–O) SH-SY5Y cells were pretreated with CSA (0.5 μM) and different kinase inhibitors for 24 h. Western blotting results revealed that those kinase inhibitors significantly inhibited CSA-mediated Nrf2 nuclear translocation, with BML-275 showing the highest inhibitory rate. HH3 was used as an internal control. All results were expressed as means ± SD of at least three independent experiments. *P < 0.05; **P < 0.01 versus control group; *P < 0.05; **P < 0.01 versus CSA group.
In conclusion, our data demonstrated that CSA had significant neuroprotective activity in OGD/R or t-BHP injured SH-SY5Y cells and MCAO/R rats. Those protective effects were exerted via activating the AMPK/Nrf2 pathway to enhance the expression of antioxidant enzymes, which then decreased the I/R induced oxidative stress and mitochondria dysfunction. This study provided scientific basis to use CSA for the prevention and treatment of ischemic stroke. However, more studies are still needed to further clarify the interaction mechanisms between AMPK and Nrf2 in the future.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This research was partially supported by HKU Seed Fund for Translational and Applied Research (201811160003).

References

[1] Chang RC, Ho YS. introductory chapter: concept of neuroprotection—a new perspective. Neurprotection. London: IntechOpen; 2019.
[2] Kunz A, Dirschl U, Mengenthaler P. Acute pathophysiological processes after ischemic and traumatic brain injury. Best Pract Res Clin Anaesthesiol 2010;24:495–509.
[3] Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropathol Perspec 2008;55:310–8.
[4] Allen CL, Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischemic stroke. Int J Stroke 2009;4:461–70.
[5] Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y. How is edaravone distributed to CSA mediated Nrf2 activation. Biomed Pharmacother 2017;88:252–9
[6] Koo MS, Kim WD, Lee KY, Kim JH, Koo JH, Kim SG. AMPK facilitates nuclear accumulation of Nrf2 by phosphorylating at serine 530. Mol Cell Biochem 2016;393:131–42.
[7] Wu C, Chen J, Yang R, Duan F, Li S, Chen X. Mitochondrial protective effect of nereine through the modulation of nuclear factor erythroid 2-related factor 2 signaling in ischemic stroke. Br J Pharmacol 2019;176:400–15.
Syed R, Wu Y. A review article on health benefits of Pigeon pea (Cajanus cajan (L.) Millsp). Nutr Res 2018;12:15.

Sun Y, Liu Y, He W, Wang C, Tickner J, Kuek V, et al. Cajaninstilbene acid inhibits osteoporosis through suppressing osteostat formation and RANKL-induced signaling pathways. J Cell Physiol 2019;234:11792–804.

Ji X, Chen J, Zheng C, Huang M, Zhang L, Yi H, et al. Design and synthesis of cajane analogue analogs against hepatitis C virus type down-regulating host chondroitin sulfate N-acetylgalactosaminyltransferase 1. J Med Chem 2016;59:10268–84.

Jiang B, Liu Y, Le L, Li Z, Si J, Liu X, et al. Cajaninstilbene acid prevents corticosterone-induced apoptosis in PC12 cells by inhibiting the mitochondrial apoptotic pathway. Cell Physiol Biochem 2014;34:1015–26.

Liang L, Luo M, Fu Y, Yu Z, Wang W, Gu C, et al. Cajaninstilbene acid (CSA) exerts cytoprotective effects against oxidative stress through the Nrf2-dependent antioxidant pathway. Toxicol Lett 2013;219:254–61.

Huang M, Lin J, Lu K, Xu H, Geng Z, Sun P, et al. Anti-inflammatory effects of cajaninstilbene acid and its derivatives. J Agric Food Chem 2016;64:2893–900.

Feng J, Chen X, Lu S, Li W, Yang D, Su W, et al. Naringin attenuates cerebral ischemia-reperfusion injury through inhibiting peroxynitrite-mediated mitophagy activation. Mol Neurobiol 2018;55:9029–42.

Lv H, Liu Q, Zhou J, Tan G, Deng X, Ci X. Daphnetin-mediated Nrf2 antioxidant signaling pathways ameliorate tert-butyl hydroperoxide (t-BHP)-induced mitochondrial dysfunction and cell death. Free Radic Biol Med 2017;106:38–52.

Duong HQ, Hwang JS, Kim HJ, Seong YS, Bae HL. BML-275, an AMPK inhibitor, induces DNA damage, G2/M arrest and apoptosis in human pancreatic cancer cells. Int J Oncol 2012;41:2227–36.

Cai SJ, Liu Y, Han S, Yang C, Brusatol, an NRF2 inhibitor for future cancer therapeutic. Cell Biosci 2019;9:45.

Mao L, Jia J, Zhou X, Xiao Y, Wang Y, Mao X, et al. Delayed administration of a PTEN inhibitor BVP improves functional recovery after experimental stroke. Neuroscience 2013;231:272–81.

Andrabi SS, Ali M, Tabassum H, Parveen S, Parvez S. Prampexolone prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech 2019;12:dmm033860.

Rogdanova A, Petrushanko Y, Hernansanz-Agustín P, Martínez-Ruiz A. “Oxygen Sensing” by Na, K-ATPase: these miraculous thiols. Front Physiol 2016;7:314.

Liu X, Zhou D, Xie T, Malik TH, Lu C, Li H, et al. Nrf2, a potential therapeutic target against oxidative stress in corneal diseases. Oxid Med Cell Longev 2017;2017:2326178.